Janelle Bradley

Conference Coverage

Workload Index Proves Valuable in Optimizing Oncology Advanced Practitioner Resourcing

11/18/2024

Findings demonstrate the success of the workload index in supporting daily and longitudinal staffing needs as well as for operational and strategic planning and has improved advanced practitioner morale by demonstrating productivity not...

Findings demonstrate the success...

11/18/2024

APP Institute Oncology

Conference Coverage

Safety and Cost-Effectiveness of CAR-T Therapy in the Outpatient vs Inpatient Setting

12/08/2021

Janelle Bradley ;

Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.

Study findings presented at the...

12/08/2021

Journal of Clinical Pathways

News

Long-term Incidence of Hematuria Following Post-Prostatectomy Radiotherapy

05/25/2022

Janelle Bradley ;

Hematuria is common following post-prostatectomy radiotherapy, particularly among patients with medication allergies and those on anticoagulation/antiplatelet therapy, according to a study published in the Journal of Urology.

Hematuria is common following...

05/25/2022

Oncology

Conference Coverage

Biomarker Testing and Alpelisib Treatment Patterns for Metastatic Breast Cancer in the Community Oncology Setting

12/07/2021

Janelle Bradley ;

A study presented at the 2021 San Antonio Breast Cancer Symposium assessed PIK3CA testing and alpelisib treatment patterns among patients with metastatic breast cancer in the community oncology setting.

A study presented at the 2021...

12/07/2021

Journal of Clinical Pathways

News

Systematic Review Highlights Complexity of Cost-Effectiveness Models in Prostate Cancer

02/22/2022

Janelle Bradley ;

This systematic review of cost-effectiveness literature for novel diagnostic methods in prostate cancer shows that most studies have found novel methods to be more cost-effective than standard of care.

This systematic review of...

02/22/2022

Journal of Clinical Pathways

Conference Coverage

Panitumumab Plus mFOLFOX6 Significantly Improves OS in Metastatic Colorectal Cancer

06/29/2022

Janelle Bradley ;

Findings from the phase 3 PARADIGM trial reveal panitumumab combined with mFOLFOX6 significantly improved OS vs bevacizumab plus mFOLFOX6 among patients with RAS wild-type and left-sided metastatic colorectal cancer.

Findings from the phase 3...

06/29/2022

Oncology

Conference Coverage

Novel Agents Preferable to Standard Chemotherapy for Salvage Treatment in LBCL Progressing After CAR-T Therapy

12/11/2022

Janelle Bradley ;

Salvage treatment with polatuzumab-containing and bispecific antibody-based regimens is preferable to standard chemotherapy for patients with relapsed/refractory LBCL, according to study findings.

Salvage treatment with...

12/11/2022

Oncology

News

Pertuzumab Added to Trastuzumab and Chemotherapy Improves Outcomes in Metastatic Breast Cancer

03/22/2022

Janelle Bradley ;

Findings from a real-world study suggest the addition of pertuzumab to trastuzumab and chemotherapy improves safety and OS for patients with metastatic breast cancer.

Findings from a real-world study...

03/22/2022

Journal of Clinical Pathways

NCCN Updates Clinical Practice Guideline for Kidney Cancer

03/24/2021

Janelle Bradley ;

On March 23, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for kidney cancer.

On March 23, 2021, the National...

03/24/2021

Journal of Clinical Pathways

Conference Coverage

Docetaxel Added to Doublet Regimen Does Not Improve Survival in Advanced GEJ/Gastric Cancers

01/18/2024

Janelle Bradley ;

The addition of docetaxel to a doublet regimen containing 5-fluorouracil/capecitabine and oxaliplatin demonstrated no improvement in OS among patients with advanced gastroesophageal junction (GEJ) and gastric cancers, according to a phase 3...

The addition of docetaxel to a...

01/18/2024

Oncology